Benzinga | Dec 1, 2020 07:38AM EST

Ruling In Tris-Teva Case Prevents Activis From Launching Generic Versions Of Quillivant Xr Until Expiration Of Patent Providing Exclusivity Until Feb 2031

-Reuters